Keymed Biosciences (2162.HK): Additional Validation for CM512: Positive Asthma Data Support Broad Respiratory Opportunity

CM512 continues to de-risk across type-2 inflammatory diseases with positive asthma data: CM512 recently reported positive Phase Ib asthma data from its overseas partner Belenos, marking the third consecutive positive clinical readout for the asset following previously reported positive data in atopic dermatitis (AD) and chronic rhinosinusitis with nasal polyps (CRSwNP). The update comes as peer lunsekimig presented detailed Phase II asthma data at ERS 2026, further validating the TSLP×IL-13 mechanism in respiratory diseases. Recall that while lunsekimig previously demonstrated successful Phase II studies in asthma and CRSwNP, its AD program failed to meet the primary endpoint (EASI score change). In contrast, CM512 has now generated encouraging efficacy signals across AD, CRSwNP and asthma, making it one of the few TSLP×IL-13 bispecific antibodies to achieve proof-of-concept across multiple major type-2 inflammatory diseases. Development for CM512 is also accelerating globally. Follow